Cargando…

New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors

As one of the most lethal diseases, pancreatic cancer shows a dismal overall prognosis and high resistance to most treatment modalities. Furthermore, pancreatic cancer escapes early detection during the curable period because early symptoms rarely emerge and specific markers for this disease have no...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xu, Xiao, Yan, Sun, Jianan, Ji, Bao, Luo, Shanshan, Wu, Bo, Zheng, Chao, Wang, Peng, Xu, Fanxing, Cheng, Keguang, Hua, Huiming, Li, Dahong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144891/
https://www.ncbi.nlm.nih.gov/pubmed/34094825
http://dx.doi.org/10.1016/j.apsb.2020.10.019
_version_ 1783697052844163072
author Hu, Xu
Xiao, Yan
Sun, Jianan
Ji, Bao
Luo, Shanshan
Wu, Bo
Zheng, Chao
Wang, Peng
Xu, Fanxing
Cheng, Keguang
Hua, Huiming
Li, Dahong
author_facet Hu, Xu
Xiao, Yan
Sun, Jianan
Ji, Bao
Luo, Shanshan
Wu, Bo
Zheng, Chao
Wang, Peng
Xu, Fanxing
Cheng, Keguang
Hua, Huiming
Li, Dahong
author_sort Hu, Xu
collection PubMed
description As one of the most lethal diseases, pancreatic cancer shows a dismal overall prognosis and high resistance to most treatment modalities. Furthermore, pancreatic cancer escapes early detection during the curable period because early symptoms rarely emerge and specific markers for this disease have not been found. Although combinations of new drugs, multimodal therapies, and adjuvants prolong survival, most patients still relapse after surgery and eventually die. Consequently, the search for more effective treatments for pancreatic cancer is highly relevant and justified. As a newly re-discovered mediator of gasotransmission, hydrogen sulfide (H(2)S) undertakes essential functions, encompassing various signaling complexes that occupy key processes in human biology. Accumulating evidence indicates that H(2)S exhibits bimodal modulation of cancer development. Thus, endogenous or low levels of exogenous H(2)S are thought to promote cancer, whereas high doses of exogenous H(2)S suppress tumor proliferation. Similarly, inhibition of endogenous H(2)S production also suppresses tumor proliferation. Accordingly, H(2)S biosynthesis inhibitors and H(2)S supplementation (H(2)S donors) are two distinct strategies for the treatment of cancer. Unfortunately, modulation of endogenous H(2)S on pancreatic cancer has not been studied so far. However, H(2)S donors and their derivatives have been extensively studied as potential therapeutic agents for pancreatic cancer therapy by inhibiting cell proliferation, inducing apoptosis, arresting cell cycle, and suppressing invasion and migration through exploiting multiple signaling pathways. As far as we know, there is no review of the effects of H(2)S donors on pancreatic cancer. Based on these concerns, the therapeutic effects of some H(2)S donors and NO–H(2)S dual donors on pancreatic cancer were summarized in this paper. Exogenous H(2)S donors may be promising compounds for pancreatic cancer treatment.
format Online
Article
Text
id pubmed-8144891
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81448912021-06-03 New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors Hu, Xu Xiao, Yan Sun, Jianan Ji, Bao Luo, Shanshan Wu, Bo Zheng, Chao Wang, Peng Xu, Fanxing Cheng, Keguang Hua, Huiming Li, Dahong Acta Pharm Sin B Review As one of the most lethal diseases, pancreatic cancer shows a dismal overall prognosis and high resistance to most treatment modalities. Furthermore, pancreatic cancer escapes early detection during the curable period because early symptoms rarely emerge and specific markers for this disease have not been found. Although combinations of new drugs, multimodal therapies, and adjuvants prolong survival, most patients still relapse after surgery and eventually die. Consequently, the search for more effective treatments for pancreatic cancer is highly relevant and justified. As a newly re-discovered mediator of gasotransmission, hydrogen sulfide (H(2)S) undertakes essential functions, encompassing various signaling complexes that occupy key processes in human biology. Accumulating evidence indicates that H(2)S exhibits bimodal modulation of cancer development. Thus, endogenous or low levels of exogenous H(2)S are thought to promote cancer, whereas high doses of exogenous H(2)S suppress tumor proliferation. Similarly, inhibition of endogenous H(2)S production also suppresses tumor proliferation. Accordingly, H(2)S biosynthesis inhibitors and H(2)S supplementation (H(2)S donors) are two distinct strategies for the treatment of cancer. Unfortunately, modulation of endogenous H(2)S on pancreatic cancer has not been studied so far. However, H(2)S donors and their derivatives have been extensively studied as potential therapeutic agents for pancreatic cancer therapy by inhibiting cell proliferation, inducing apoptosis, arresting cell cycle, and suppressing invasion and migration through exploiting multiple signaling pathways. As far as we know, there is no review of the effects of H(2)S donors on pancreatic cancer. Based on these concerns, the therapeutic effects of some H(2)S donors and NO–H(2)S dual donors on pancreatic cancer were summarized in this paper. Exogenous H(2)S donors may be promising compounds for pancreatic cancer treatment. Elsevier 2021-05 2020-10-31 /pmc/articles/PMC8144891/ /pubmed/34094825 http://dx.doi.org/10.1016/j.apsb.2020.10.019 Text en © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Hu, Xu
Xiao, Yan
Sun, Jianan
Ji, Bao
Luo, Shanshan
Wu, Bo
Zheng, Chao
Wang, Peng
Xu, Fanxing
Cheng, Keguang
Hua, Huiming
Li, Dahong
New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors
title New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors
title_full New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors
title_fullStr New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors
title_full_unstemmed New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors
title_short New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors
title_sort new possible silver lining for pancreatic cancer therapy: hydrogen sulfide and its donors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144891/
https://www.ncbi.nlm.nih.gov/pubmed/34094825
http://dx.doi.org/10.1016/j.apsb.2020.10.019
work_keys_str_mv AT huxu newpossiblesilverliningforpancreaticcancertherapyhydrogensulfideanditsdonors
AT xiaoyan newpossiblesilverliningforpancreaticcancertherapyhydrogensulfideanditsdonors
AT sunjianan newpossiblesilverliningforpancreaticcancertherapyhydrogensulfideanditsdonors
AT jibao newpossiblesilverliningforpancreaticcancertherapyhydrogensulfideanditsdonors
AT luoshanshan newpossiblesilverliningforpancreaticcancertherapyhydrogensulfideanditsdonors
AT wubo newpossiblesilverliningforpancreaticcancertherapyhydrogensulfideanditsdonors
AT zhengchao newpossiblesilverliningforpancreaticcancertherapyhydrogensulfideanditsdonors
AT wangpeng newpossiblesilverliningforpancreaticcancertherapyhydrogensulfideanditsdonors
AT xufanxing newpossiblesilverliningforpancreaticcancertherapyhydrogensulfideanditsdonors
AT chengkeguang newpossiblesilverliningforpancreaticcancertherapyhydrogensulfideanditsdonors
AT huahuiming newpossiblesilverliningforpancreaticcancertherapyhydrogensulfideanditsdonors
AT lidahong newpossiblesilverliningforpancreaticcancertherapyhydrogensulfideanditsdonors